Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry

Gastroenterology

Volumn 137, Issue 2, 2009, Pages 673-681

  Matsumura, Takuya ^a   Hu, Zongyi ^a   Kato, Takanobu ^a   Dreux, Marlene ^b   Zhang, Yong Yuan ^a   Imamura, Michio ^c   Hiraga, Nobuhiko ^c   Juteau, Jean Marc ^d   Cosset, Francois Loic ^b   Chayama, Kazuaki ^c   Vaillant, Andrew ^d   Liang, T Jake ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITÉ DE LYON   (France)

^c HIROSHIMA UNIVERSITY   (Japan)

^d REPLICor Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; DNA; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; UROKINASE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL ADHESION; CONTROLLED STUDY; ENGRAFTMENT; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY; VIRUS PARTICLE; VIRUS REPLICATION;

EID: 67650973623     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.04.048     Document Type: Article

References (44)

1. Liang T.J., Rehermann B., Seeff L.B., et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132 (2000) 296-305
2. Feld J.J., and Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005) 967-972
3. Pawlotsky J.M. Therapy of hepatitis C: from empiricism to eradication. Hepatology 43 (2006) S207-S220
4. Smith A.E., and Helenius A. How viruses enter animal cells. Science 304 (2004) 237-242
5. Bartosch B., Dubuisson J., and Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197 (2003) 633-642
6. Evans M.J., von Hahn T., Tscherne D.M., et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446 (2007) 801-805
7. Hsu M., Zhang J., Flint M., et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 100 (2003) 7271-7276
8. Lindenbach B.D., Evans M.J., Syder A.J., et al. Complete replication of hepatitis C virus in cell culture. Science 309 (2005) 623-626
9. Lozach P.Y., Lortat-Jacob H., de Lacroix de Lavalette A., et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem 278 (2003) 20358-20366
10. Scarselli E., Ansuini H., Cerino R., et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21 (2002) 5017-5025
11. Bartosch B., Vitelli A., Granier C., et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278 (2003) 41624-41630
12. Koutsoudakis G., Kaul A., Steinmann E., et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 80 (2006) 5308-5320
13. Rusconi S., Scozzafava A., Mastrolorenzo A., et al. An update in the development of HIV entry inhibitors. Curr Top Med Chem 7 (2007) 1273-1289
14. Vaillant A., Juteau J.M., Lu H., et al. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Antimicrob Agents Chemother 50 (2006) 1393-1401
15. Wakita T., Pietschmann T., Kato T., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11 (2005) 791-796
16. Lavillette D., Tarr A.W., Voisset C., et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41 (2005) 265-274
17. Owsianka A., Tarr A.W., Juttla V.S., et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79 (2005) 11095-11104
18. Kato T., Date T., Miyamoto M., et al. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol 43 (2005) 5679-5684
19. Nanda S.K., Herion D., and Liang T.J. The SH3 binding motif of HCV (corrected) NS5A protein interacts with Bin1 and is important for apoptosis and infectivity. Gastroenterology 130 (2006) 794-809
20. Triyatni M., Saunier B., Maruvada P., et al. Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J Virol 76 (2002) 9335-9344
21. Lavillette D., Bartosch B., Nourrisson D., et al. Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. J Biol Chem 281 (2006) 3909-3917
22. Tateno C., Yoshizane Y., Saito N., et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165 (2004) 901-912
23. Lamond A.I., and Sproat B.S. Antisense oligonucleotides made of 2′-O-alkylRNA: their properties and applications in RNA biochemistry. FEBS Lett 325 (1993) 123-127
24. Steinmann D., Barth H., Gissler B., et al. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol 78 (2004) 9030-9040
25. Baumert T.F., Vergalla J., Satoi J., et al. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology 117 (1999) 1397-1407
26. Wellnitz S., Klumpp B., Barth H., et al. Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol 76 (2002) 1181-1193
27. Pawlotsky J.M., Chevaliez S., and McHutchison J.G. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132 (2007) 1979-1998
28. Agrawal S., Tang J.Y., and Brown D.M. Analytical study of phosphorothioate analogues of oligodeoxynucleotides using high-performance liquid chromatography. J Chromatogr 509 (1990) 396-399
29. Lee A.M., Rojek J.M., Gundersen A., et al. Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. Virology 372 (2008) 107-117
30. Moulard M., Lortat-Jacob H., Mondor I., et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 74 (2000) 1948-1960
31. Barth H., Schafer C., Adah M.I., et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278 (2003) 41003-41012
32. Kim J., Cheong C., and Moore P.B. Tetramerization of an RNA oligonucleotide containing a GGGG sequence. Nature 351 (1991) 331-332
33. Preiss S., Thompson A., Chen X., et al. Characterization of the innate immune signalling pathways in hepatocyte cell lines. J Viral Hepat 15 (2008) 888-900
34. Kielian M., and Rey F.A. Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol 4 (2006) 67-76
35. Kielian M. Class II virus membrane fusion proteins. Virology 344 (2006) 38-47
36. Lescar J., Roussel A., Wien M.W., et al. The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell 105 (2001) 137-148
37. Yagnik A.T., Lahm A., Meola A., et al. A model for the hepatitis C virus envelope glycoprotein E2. Proteins 40 (2000) 355-366
38. Yu X., Qiao M., Atanasov I., et al. Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. Virology 367 (2007) 126-134
39. Tscherne D.M., Jones C.T., Evans M.J., et al. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 80 (2006) 1734-1741
40. Cormier E.G., Tsamis F., Kajumo F., et al. CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A 101 (2004) 7270-7274
41. Bartosch B., Verney G., Dreux M., et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 79 (2005) 8217-8229
42. Dreux M., Boson B., Ricard-Blum S., et al. The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus. J Biol Chem 282 (2007) 32357-32369
43. Samuel D., Bizollon T., Feray C., et al. Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 124 (2003) 642-650
44. Schiano T.D., Charlton M., Younossi Z., et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 12 (2006) 1381-1389